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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is an independent risk factor for cardiovascular
(CV) disease, one of the most frequent causes of death in COPD patients. The goal of the present study was
to evaluate the prognostic value of non-invasive CV risk markers in COPD patients.
Methods: CV risk was prospectively evaluated in 287 COPD patients using non-invasive markers including the
Framingham score, the Systematic Coronary Risk Evaluation (SCORE) charts, coronary arterial calcium (CAC),
epicardial adipose tissue (EAT), as well as clinical, biochemical and physiological variables. The predictive
power of each parameter was explored using CV events as the main outcome.
Results: During a median follow up of 65 months (ICR: 36–100), 44 CV events were recorded, 12 acute
myocardial infarctions (27.3%), 10 ischemic heart disease/angina (22.7%), 12 peripheral artery disease events
requiring surgery (27.3%) and 10 strokes (22.7%). A total of 35 CV deaths occurred during that period. Univariable
analysis determined that age, hypertension, CRP, total Cholesterol, LDL-Cholesterol, Framingham score and CAC were
independently associated with CV events. Multivariable analysis identified CAC as the best predictor of CV events (HR;
95%CI: 1.32; 1.19–1.46, p < 001).
Conclusions: In COPD patients attending pulmonary clinics, CAC was the best independent non-invasive predictor of
CV events. This tool may help evaluate the risk for a CV event in patients with COPD. Larger studies should reproduce
and validate these findings.
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What is the key question?
COPD patients are at high risk of major cardiovascular
(CV) events. Several non-invasive CV risk markers have
been proposed to predict these events in the general
population but never been compared in COPD patients.
What is the bottom line?
Coronary Artery Calcium (CAC) is the best non-invasive
CV risk marker that predicts major CV events in this
population of COPD patients.
Why read on?
The incorporation of this tool into daily practice of prac-
titioners caring for patients with COPD could help
detect high risk patients for future major CV events.
Background
Chronic Obstructive Pulmonary Disease (COPD) and
cardiovascular disease (CV) are two of the leading
causes of death in the world [1]. Several studies have
demonstrated the close relationship between COPD and
CV disease [2, 3]. Patients suffering from coronary artery
disease (CAD) that also have COPD, double the risk of
death from CV disease compared to patients without
COPD [3]. On the other hand, patients with COPD are
at greater risk of morbidity and mortality from CV
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disease [4, 5]. According to several studies CV deaths
are amongst the major causes of death in patients with
COPD especially in those with mild to moderate degree
of airway obstruction [6–9].
Although the recent update of the COPD GOLD guide-
lines recommend an evaluation for the presence of associ-
ated comorbidities [10], they do not specify how to
evaluate pre-symptomatic patients through the use of
non-invasive tools. The guidelines only state that clini-
cians should use the same methodology used in patients
without the disease, but the potential use of non-invasive
tools in the evaluation of future risk for CV events in
these patients has not been investigated. A recent system-
atic review and meta-analysis [11] highlighted the need for
the development of strategies to screen for CV risk factors
in patients with COPD.
In order to help clinicians caring for COPD patients
better detect risk of future CV events, we decided to
evaluate the ability of different non-invasive tools in pre-
dicting cardiovascular events in a population of real-life
patients with COPD attending pulmonary clinics.
Methods
Participants were former and current smokers of at least
10 pack-years with previous spirometric diagnosis of
COPD and regularly seen in our pulmonary clinic. All pa-
tients signed the consent form previously approved by the
Human Review Board (Pamplona: “Comité de Etica de la
Investigación, Universidad de Navarra IRB n°: 043/2006”).
Subjects were consecutively enrolled from January 2006 to
March 2016. COPD was confirmed by history and a post-
bronchodilator Forced Expiratory Volume in the first sec-
ond (FEV1)/Forced Vital Capacity (FVC) ratio of less than
0.7. All post bronchodilation measurements were per-
formed 15 min after the inhalation of 400 μg of albuterol.
To be enrolled, COPD patients had to be clinically stable
and without exacerbations for 8 weeks prior to entry, and
receiving optimal therapy according to international
guidelines [10]. Exclusion criteria were uncontrolled co-
morbidities such as malignancy or other confounding dis-
eases. We recorded their previous history of diabetes mel-
litus (DM), hypertension (HTA), dyslipidemia, and the use
of anti-hypertensive medications or statins. Blood pressure
was measured following standard recommendations [12].
Patients with a history of a previous major CV event:
acute myocardial infarction (AMI), ischemic heart dis-
ease/angina events or peripheral artery disease required
surgery or a stroke, were not included in the study as
shown in Fig. 1.
Clinical variables
Lung volumes and spirometry were measured according to
the ATS/ERS guidelines [13]. The 6-min walking distance
(6MWD) was selected from the best of two walks separated
by at least 30 min as recommended by the guidelines [14]
(21). Modified Medical Research Council (MMRC) scale
[15] evaluated patients` dyspnea. Body Mass Index (BMI)
was calculated in kg/m [2]. FEV1% of predicted values,
BMI, 6MWD and MMRC values were integrated into the
BODE index [16] as previously described.
Cardiovascular risk assessment scores
The validated tools explored in this study are summa-
rized in the on-line supplement. They included the Fra-
mingham score and the Systematic Coronary Risk
Evaluation (SCORE) charts [17, 18]. In brief, these scores
include anthropological details, smoking, presence of
DM, lipid profile and blood pressure.
Laboratory measurements
Morning fasting blood and spot-urine samples were col-
lected simultaneously while at rest and before any other
test. The microalbuminuria (MAB) or urinary albumin
excretion was determined as the urine albumin (milli-
grams) to creatinine (grams) ratio in the morning urine.
Urine albumin concentration was determined by a
standard turbidometric method (coefficient of variation
5.5%). Serum and urine creatinine concentrations were
analyzed using the Jaffe reaction and quantified by a
photometric method. Fasting serum levels of glucose,
high sensitivity CRP, glycated haemoglobin (HbA1c) and
cholesterol were also determined.
CT Image acquisition and reconstruction protocol
All individuals were enrolled in a lung cancer screening
program [19] and underwent a low radiation dose chest CT
Fig. 1 Flow diagram of the enrolment process and the patients
included in the study
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examination using a multidetector CT system (Somatom
Definition and Somatom Sensation 64, Siemens Healthcare,
Forchheim, Germany). Low-dose chest CT was performed
with 120 kV, 40 mAs, 32 × 0.6 mm detector collimation,
64 × 0.6 mm slice acquisition, 0.5 s gantry rotation time,
and 1.4 pitch. Images were reconstructed with 5-mm slice
thickness using soft-tissue convolution kernel (B31f). No
intravenous contrast was administered.
Epicardial Adipose Tissue (EAT) Quantification
EAT volume was assessed by two independent observers
(JZ, GB) unaware of the clinical information, using a
commercially available software tool (Volume, Siemens)
based on attenuation-dependent segmentation methods.
Concordance coefficient between observers was 0.95;
(95% CI: 0.93–0.96). Observers manually traced the peri-
cardium at its superior extent (the center of the right
pulmonary artery as it crosses the mid-sagittal plane), at
mid-ventricular level, and at the end of the pericardial
sac, which defined the inferior extent of the pericardial
volume. The software automatically interpolated be-
tween the user-defined traces. Automatically traced con-
tours were manually adjusted to the pericardium if
needed. Epicardial adipose tissue volume was defined as
any fat tissue located within the pericardial sac. A prede-
fined threshold of −195 to −45 HU was used to identify
voxels corresponding to fat [20].
Coronary Calcium Calcification Evaluation
Each of the four main coronary arteries was identified
(left main, left anterior descending, circumflex, and
right). Calcification in each artery was categorized as ab-
sent, mild, moderate, or severe and scored by the radi-
ologist as 0, 1, 2, or 3, respectively. Calcification was
classified as mild when less than one-third of the length
of the entire artery showed calcification, moderate when
one-third to two-thirds of the artery showed calcifica-
tion, and severe when more than two-thirds of the artery
showed calcification. With four arteries thus scored,
each subject received a coronary arterial calcium (CAC)
score ranging from 0 to 12 [21].
Outcome adjudication
Major CV events (AMI, ischemic heart disease/angina
events, peripheral artery disease required surgery or a
stroke) or deaths were registered reviewing each patient
chart or contacting their family members.
Statistical analysis
Data was summarized as relative frequencies for categor-
ical variables, mean (SD) for normally distributed variables
and median (25th–75th percentile) for non-normal data.
To explore the association between Framingham score
and CV event we used Spearman’s correlation coefficient.
To determine which factors best predicted the risk of
developing a CV event, a Cox analysis was used. We first
performed a univariable analysis with CAC, age, hyper-
tension, total cholesterol, LDL-cholesterol, Framingham
score, and SCORE charts and then a multivariable ana-
lysis including those that were statistically significant in
the univariate analysis (p < 0.05). Because most of the
factors found to be independently associated with CV
events in the univariable analysis are included also in the
Framingham score, we only compared this score and
CRP levels with CAC in the multivariable analysis.
Significance level was established as a two-tailed p-
Value ≤0.05. Calculations were made with SPSS 15.0,
Chicago, U.S.A.
Results
Figure 1 shows the flow diagram of the enrolment
process. From the initial sample of 350 former and
current smokers with COPD, we were able to enroll 287
patients without a previous history of CV events. All de-
grees of airway obstruction severity were included. The
clinical, radiological and physiological characteristics of
the patients are shown in Table 1.
The median follow-up time was 65 months (interquar-
tile range: 36–100 months), and during this period 44
CV events were recorded: 12 (27.3%) acute myocardial
infarction (AMI), 10 (22.7%) ischemic heart disease/an-
gina events, 12 (27.3%) peripheral artery disease events
requiring surgery and 10 (22.7%) strokes. In addition 35
deaths occurred during this period, 6 (17.5%) due to car-
diac causes, 16 (46%) due to respiratory causes, 4 (11%)
due to lung cancer, 5 (14.5%) due to other cancers, and
4 (11%) from other causes.
No differences were found in FEV1 in L (1.99 ± 0.7 vs
1.98 ± 0.7, p = 0.93) or % predicted (70 ± 22 vs 70 ± 21,
p = 0.96) between those with and without a CV event
respectively.
Table 2 shows the proportion of patients in each Fra-
mingham Score Risk category according to their spiromet-
ric GOLD groups. As expected, the risk of developing a
CV event of a COPD patient is highly independent of their
degree of airflow limitation. The small number of subjects
included in grade 4, does not allow to obtain solid conclu-
sion. The correlation between the Framingham score and
the number of CV events was weak (r = 0.19) although
statistically significant (p = 0.001).
Table 3 shows the Cox univariable analysis that ex-
plores the independent association of each of the evalu-
ated non-invasive CV risk factors with the risk of
developing a CV event. The parameters that showed
statistical significance were age, history of HTA, CRP
levels, total cholesterol, LDL-cholesterol, CAC and the
Framingham index. Interestingly, three well established
noninvasive CV markers like Urine Albumin/Creatinine
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ratio, SCORE and EAT were not associated with the risk
of developing a CV event. In Table 4, the multivariable
analysis shows that CAC was the solely variable that
remained in the model.
Discussion
The present study of patients with COPD attending our
clinic shows that amongst the clinical, radiological and
laboratory tools available to clinicians, the CAC score is
the most powerful tool to evaluate the risk of suffering a
major CV event in this high risk population.
It has been shown that additive models of individuals
CV risk factors do not explain their interaction and syn-
ergy between variables and outcomes. Therefore, in the
last decades, the concept of global risk assessment has
been developed. One of the first tools to evaluate this
global risk assessment was the one proposed by the





Age (years) 64 ± 9
Follow up (months) 65 (36–100)
Gender (%) male/female 83/17
Pack-year (units) 51 ± 27
Current Smoker (%) yes/no 50/50
Framingham index (%) 27 (17–42)
SCORE index (%) 4 ± 3
Charlson (Units) 1 (1–2)
BMI (Kg/m2) 27.3 ± 4.8
FEV1/FVC (%) 55 ± 11
FEV1 (liters) 2.18 ± 0.8
FEV1% 70 ± 22
FVC % 99 ± 20
TLC % 106 ± 15
IC/TLC 0.33 ± 0.1
MMRC 0–4 (%) 36/32/21/9/2
6MWD (m) 465 ± 114
BODE Quart 1–4 (%) 82/10/5/3
Hypertension (%) yes/no 36/64
Anti-hypertensive treatment (%) yes/no 65/35
SBP (mmHg) 129 ± 19
DBP (mmHg) 76 ± 10.4
DM (%) yes/no 11/89
Glucose (mg/dL) 97 (90–108)
HbA1c % 5.9 (5.6–6.5)
Dyslipidemia (%) yes/no 71/29
Anti-hyperlipidemia treatment (%)yes/no 73/27
Total Cholesterol (mg/dL) 202 (172–232)
LDL-C (mg/dL) 124 (97.3–156)
HDL-C (mg/dL) 50 (41–61.8)
Urine Albumin/Creatinine ratio (mg/g) 12.8 (6–32.6)
EAT (cm3) 153 (112–211)
Coronary Calcium Score (Units) 2 (1–3)
CRP (mg/dL) 0.4 (0.2–0.8)
Systemic corticosteroid treatment (%) yes/no 6/94
n Number of participants, BMI Body Mass Index, FEV1 Forced Expiratory
Volume in the first second, FVC Forced Vital Capacity, TLC Total Lung Capacity,
MMRC Modified Medical research Council, 6MWD 6 Minute Walk Distance,
BODE index BMI, Obstruction, Dyspnea, Exercise, SBP Systolic Blood Pressure,
DBP Dyastolic Blood Pressure, DM Diabetes Mellitus, LDL-C Low Density
Protein, HDL-C High Density Protein, EAT Epicardial Adipose Tissue, CRP C
reactive Protein
X ± SD means ± Standart Deviation, p25-p75 interquartile range




Framingham Score Risk Category
<10% 10–20% >20%
1 FEV1% > 80 (n = 109) 9 21 70
2 FEV1% 50–79 (n = 112) 8 20 72
3 FEV1% 30–49 (n = 53) 8 18 74
4 FEV1% < 30 (n = 13) 23 15 61
Table 3 Univariable analysis showing the independent association
of each non-invasive CV risk marker with the risk of major CV event
Univariate analyses exploring factors that predict CV events
Variable HR (95% IC) p
Age (year) 1.06 (1.03–1.08) 0.001
Pack-year (index) 1.01 (1.00–1.02) 0.003
BMI (index) 0.98 (0,94–1,03) 0,52
Gender (m/f) 0.59 (0.31–1.11) 0.10
Current Smoker (y/n) 0.53 (1.00–2.32) 0.04
FEV1% 0.99 (0.98–1.00) 0.07
Hypertension 2.53 (1.67–3.83) 0.001
DM 2.01 (1.22–2.32) 0.006
CRP (mg/dL) 1.24 (1.01–1.52) 0.03
Total Cholesterol (mg/dL) 0.99 (0.98–0.99) 0.007
HDL-C (mg/dL) 0.99 (0.98–1.00) 0.42
LDL-C (mg/dL) 0.98 (0.98–0.99) 0.001
Urine Albumin/Creatinine ratio 1.00 (0.99–1.00) 0.75
Framingham (for each %) 1.01 (1.00–1.03) 0.002
SCORE (for each %) 1.05 (0.98–1.11) 0.14
EAT (cm3) 1.00 (0.99–1.004) 0.27
Coronary Calcium Score (unit) 1.36 (1.24–1.48) 0.001
BMI Body Mass Index, DM Diabetes Mellitus, HDL-C High Density Protein, LDL-C
Low Density Protein, EAT Epicardial Adipose Tissue
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Framingham study through its index [20]. Although this
index has been extensively validated [22], it has several
limitations. First, it only included patients from the
United States not including other populations with dif-
ferent daily life activity and dietary habits. As an ex-
ample, it has been shown that this index overestimates
the CV risk in the European population [23]. To over-
come this important limitation, European researchers
have developed the SCORE study that validated the
SCORE charts [18]. Interestingly, in our population of
patients with COPD studied in Spain, the Framingham
score showed statistical association, but only in the uni-
variable analysis. Surprisingly the SCORE chart was not
statistically significant even in the univariable analysis.
Using the Framingham score, the estimated incidence of
yearly CV events was 2.7% (27% estimate at 10 years),
very similar to that observed after 5 years of follow up:
15% (3% per year). This confirms that COPD patients
fall into the high-risk group (estimated 10 year CV
risk > 20% for a mainly male cohort) for CV events. This
is the first time the value of the Framingham score is
validated in a COPD population.
Calcification of the coronary is an active process and
can be seen in each of the stages of the development of
an atherosclerotic plaque. The presence of calcium in
the coronary artery is pathognomonic of coronary ath-
erosclerosis, confirmed by histopathology and intravas-
cular ultrasound studies [24–27]. Therefore, the CAC
detected by chest CT is useful in estimating the burden
of coronary atherosclerosis, and may be an effective tool
for CV risk stratification in asymptomatic patients [21].
The absence of CAC in adults without evidence of CV
disease excludes the presence of significant coronary
atherosclerosis, which results in CV mortality rate of
around 1% in 10 years [28, 29]. A recently published
study by Williams et al. [30] confirmed that COPD pa-
tients have more CAC than controls and this is associ-
ated with increased dyspnea, reduced exercise capacity
and increased general mortality. However, this study of
the Evaluation of COPD Longitudinally to Identify Pre-
dictive Surrogate Endpoints (ECLIPSE) database only
evaluated global mortality and not specifically CV deaths
or CV events, and did not compare the predictive power
of CAC with other well established noninvasive CV risk
factors like cholesterol levels, CRP, microalbuminuria,
Framingham score or SCORE charts. The current study
shows that compared with other cardiovascular risk fac-
tors, the evaluation of CAC by a low dose chest CT is
the best predictor of cardiovascular events in COPD pa-
tients (HR = 1.29; 1.08–1.56). This finding is important
since to date, no information was available about the po-
tential value of the CAC as a predictor of cardiovascular
events in patients with COPD, and no data was available
even in the general Spanish population. Results from the
current study of COPD patients confirms that the pres-
ence of CAC is a good predictor of CV events, even
when compared with the Framingham index [31–39].
The present study showed that elevated levels of CRP
were associated with major CV events in the univariable
analysis. Previously, Park et al. [40] studied 4905 adult
males and showed that lower FEV1 was associated with
higher levels of serum CRP, and a higher frequency of
metabolic syndrome and coronary artery calcification on
chest CT. However, in our study, the association between
CRP level and CV events lost significance when compared
with other noninvasive CV risk factors like CAC.
Interestingly, Romundstad et al. [41], exploring the
Nord-Trøndelag Health Study (HUNT) database, found
that MAB was associated with global mortality in COPD
patients but not with CV mortality, as the present study
did. These authors suggested that MAB could reflect the
low grade systemic inflammation process, independent
of the development of atherosclerosis.
Two unexpected findings from the present work were
that SCORE and EAT were not associated with the de-
velopment of CV event. As far as we can tell, this is the
first time that these two well established noninvasive CV
markers are specifically explored in a COPD population.
They have been shown to predict CV outcomes in the
general population but maybe for these specific markers
we need a larger population and a longer follow up time
if they are to be useful in patients with COPD.
The main strength of the present study is that it
explored clinical, analytical and radiological non-invasive
CV risk markers in a population of COPD patients pro-
spectively followed for a long period of time. It also
explored, for the first time, the potential utility of com-
monly used CV risk assessment tools like the Framingham
index and the SCORE charts in this high risk population.
The present study also had several limitations. Firstly, it
was conducted in Caucasian patients with COPD followed
in a tertiary center University Hospital and therefore the
findings may not be applicable to the general population
of patients with COPD. Secondly, a limited proportion of
women were included in this study (although an equal
opportunity to participate was offered) precluding the ex-
trapolation of these findings to women with COPD.
Thirdly, most patients included in the study had mild to
moderate COPD, however, there is sufficient evidence
Table 4 The multivariable analysis indicated the Coronary
Calcium score had a higher predictive power for risk of
major CV event compared to the Framingham score
Multivariate analyses to exploring factors that predict CV events
Variables Coefficient IC p
Coronary Calcium Score (for each %) 1.32 1.19–1.46 0.001
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showing that patients with mild to moderate COPD are
the ones with higher risk of CV diseases [8, 42].
Our findings also convey a practical message. The use
of CT scans of the thorax is increasing and this informa-
tion may actually extends the use of such a tool, to help
identify those subject within the COPD population were
preventive measures such as smoking cessation, exercise
promotion, detection and control of diabetes and dyslip-
idemia may help avoid subsequent CV events.
Conclusions
In this cohort of patients with COPD from a pulmonary
clinic of a tertiary University Hospital, CAC was the best
predictor of CV events independently of other CV risk
factors. If larger studies in different settings validate
these findings, the incorporation of this tool to the prac-
tice of practitioners caring for patients with COPD could
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